NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $43.33.
Several analysts recently weighed in on NAMS shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th.
Get Our Latest Report on NewAmsterdam Pharma
Insiders Place Their Bets
Hedge Funds Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $50,000. National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma during the fourth quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Finally, Legal & General Group Plc increased its stake in NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock valued at $590,000 after purchasing an additional 4,556 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.
NewAmsterdam Pharma Trading Down 0.1 %
Shares of NASDAQ:NAMS opened at $23.34 on Tuesday. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -8.98 and a beta of -0.04. NewAmsterdam Pharma has a 12-month low of $15.19 and a 12-month high of $27.29. The business has a 50-day moving average price of $21.90 and a 200 day moving average price of $20.83.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- What is the Nikkei 225 index?
- Can TikTok Stock Picks Really Make You Rich?
- Growth Stocks: What They Are, What They Are Not
- The “Quality” Rotation: Back to Basics Investing
- There Are Different Types of Stock To Invest In
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.